JP2022523200A5 - - Google Patents

Info

Publication number
JP2022523200A5
JP2022523200A5 JP2021549538A JP2021549538A JP2022523200A5 JP 2022523200 A5 JP2022523200 A5 JP 2022523200A5 JP 2021549538 A JP2021549538 A JP 2021549538A JP 2021549538 A JP2021549538 A JP 2021549538A JP 2022523200 A5 JP2022523200 A5 JP 2022523200A5
Authority
JP
Japan
Prior art keywords
drawings
invention substantially
substantially described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523200A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019978 external-priority patent/WO2020176672A1/en
Publication of JP2022523200A publication Critical patent/JP2022523200A/ja
Publication of JP2022523200A5 publication Critical patent/JP2022523200A5/ja
Pending legal-status Critical Current

Links

JP2021549538A 2019-02-26 2020-02-26 活性化可能な免疫チェックポイント阻害剤とコンジュゲートされた活性化可能な抗体の組み合わせ療法 Pending JP2022523200A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962810698P 2019-02-26 2019-02-26
US62/810,698 2019-02-26
US201962825228P 2019-03-28 2019-03-28
US62/825,228 2019-03-28
PCT/US2020/019978 WO2020176672A1 (en) 2019-02-26 2020-02-26 Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies

Publications (2)

Publication Number Publication Date
JP2022523200A JP2022523200A (ja) 2022-04-21
JP2022523200A5 true JP2022523200A5 (cg-RX-API-DMAC7.html) 2023-03-03

Family

ID=69960745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549538A Pending JP2022523200A (ja) 2019-02-26 2020-02-26 活性化可能な免疫チェックポイント阻害剤とコンジュゲートされた活性化可能な抗体の組み合わせ療法

Country Status (5)

Country Link
US (1) US20220233705A1 (cg-RX-API-DMAC7.html)
EP (1) EP3930761A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022523200A (cg-RX-API-DMAC7.html)
CN (1) CN113677372A (cg-RX-API-DMAC7.html)
WO (1) WO2020176672A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023872A2 (pt) 2015-05-04 2018-07-24 Cytomx Therapeutics Inc anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
US20230408498A1 (en) * 2020-10-13 2023-12-21 Cz Biohub Sf, Llc Compositions and methods involving antibody constructs
EP4496816A1 (en) 2022-03-23 2025-01-29 CytomX Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
JP2025512798A (ja) 2022-03-25 2025-04-22 サイトムエックス セラピューティクス,インク. 活性化可能な二重アンカー型マスク化分子及びその使用方法
WO2023192973A1 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
EP4504782A2 (en) 2022-04-01 2025-02-12 CytomX Therapeutics, Inc. Cd3-binding proteins and methods of use thereof
WO2024030845A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
US20260015425A1 (en) 2022-08-01 2026-01-15 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
JP2025525868A (ja) 2022-08-01 2025-08-07 サイトムエックス セラピューティクス,インク. プロテアーゼ切断性部分及びその使用方法
AR130077A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Substratos escindibles por proteasas, y métodos de uso de los mismos
TW202424184A (zh) 2022-08-01 2024-06-16 美商Cytomx生物製藥公司 蛋白酶可切割部分及其使用方法
CN120958015A (zh) 2023-04-12 2025-11-14 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
EP4694934A1 (en) 2023-04-12 2026-02-18 CytomX Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods
WO2026024841A1 (en) 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
WO2026035650A2 (en) 2024-08-05 2026-02-12 Cytomx Therapeutics, Inc. Cleavable polypeptides and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
WO2007027935A2 (en) 2005-08-31 2007-03-08 The Regents Of The University Of California Cellular libraries of peptide sequences (clips) and methods of using the same
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
WO2010129609A2 (en) 2009-05-07 2010-11-11 The Regents Of The University Of California Antibodies and methods of use thereof
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
EP2882844B1 (en) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
BR112015030514A2 (pt) * 2013-06-04 2017-08-29 Cytomx Therapeutics Inc Composições e métodos para conjugação de anticorpos ativáveis
MA42971A (fr) * 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
BR112017023872A2 (pt) * 2015-05-04 2018-07-24 Cytomx Therapeutics Inc anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
MX383464B (es) * 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
CN110914302A (zh) * 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法

Similar Documents

Publication Publication Date Title
JP2024023385A5 (cg-RX-API-DMAC7.html)
JP2022028828A5 (cg-RX-API-DMAC7.html)
JP2021169491A5 (cg-RX-API-DMAC7.html)
JP2022025124A5 (cg-RX-API-DMAC7.html)
JP2021185136A5 (cg-RX-API-DMAC7.html)
JP2022068302A5 (cg-RX-API-DMAC7.html)
JP2020127428A5 (cg-RX-API-DMAC7.html)
JP2021028398A5 (cg-RX-API-DMAC7.html)
JP2021038271A5 (cg-RX-API-DMAC7.html)
JP2023022224A5 (cg-RX-API-DMAC7.html)
JP2024016014A5 (cg-RX-API-DMAC7.html)
JP2020042034A5 (cg-RX-API-DMAC7.html)
JP2023100643A5 (cg-RX-API-DMAC7.html)
JP2021518389A5 (cg-RX-API-DMAC7.html)
JP2025506484A5 (cg-RX-API-DMAC7.html)
JP2022060295A5 (cg-RX-API-DMAC7.html)
JP2020171301A5 (cg-RX-API-DMAC7.html)
JP2020120660A5 (cg-RX-API-DMAC7.html)
JP2023085551A5 (cg-RX-API-DMAC7.html)
JP2022537813A5 (cg-RX-API-DMAC7.html)
JP2021524864A5 (cg-RX-API-DMAC7.html)
JP2023011759A5 (cg-RX-API-DMAC7.html)
JP2024534771A5 (cg-RX-API-DMAC7.html)
JP2020141705A5 (cg-RX-API-DMAC7.html)
JP2020521447A5 (cg-RX-API-DMAC7.html)